Monoclonal antibodies to IL-6R, such as tocilizumab or sarilumab, were of great interest as potential treatments for severe COVID-19; however, enthusiasm about their use in advance of strong evidence was tempered by concerns about the increased risk of bacterial infections in patients receiving the drug long-term. Here, IL6R is linked to COVID-19.